HiberCell, a new startup focused on preventing cancer metastasis and relapse, launched Thursday with research out of Mount Sinai and $60.75 million from the likes of ARCH Venture Partners, Hillhouse Capital and 6 Dimensions Capital. 

The company reckons it is the first to exclusively focus on detecting and treating tumor dormancy that can lead to cancer spread. 

“While we have made great strides in treating primary tumors, the unfortunate and painful truth is that relapsed or metastatic cancer still claims the lives of most people with cancer, even when their primary tumor has been successfully treated,” said Julio Aguirre-Ghiso, Ph.D., HiberCell’s scientific founder and a professor at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. 


Read the full story in FierceBiotech